# Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma

> **NCT03456466** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 122 (estimated)

## Conditions studied

- Non-hodgkin's Lymphoma

## Interventions

- **DRUG:** TQB2303
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03456466
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-01
- **Primary completion:** 2018-06-30
- **Final completion:** 2018-06-30
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2018-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03456466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03456466, "Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03456466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*